Get Support

Search global stocks & ETFs...Ctrl K

Learn Mode

IBRX - Immunitybio Inc

15

$8.12

$0.01 (0.123%)

At market close

$8.14

$0.02 (0.259%)

After Hours 5/12/26, 11:58 PM

2.67/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

IBRX

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$8.50B

Industry

Biotechnology

EPS (TTM)

-$0.35

P/E (TTM)

0.00

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

75.07

P/B

0.00

Diluted Shares

990.45M

Ex-Dividend

--

Next Earnings

08-03

Forward P/E

0.00

Payout Ratio

--

P/FCF (TTM)

0.00

FCF Yield

--

Earnings Yield

-4.13%

52 Week Range

Score Card

Explore Scores Tab

2.67

Average

Immunitybio Inc has negative free cash flow of -309.19M, which means it is currently losing money. Also, it has a current cash runway of 9.42 months. The cash runway is the amount of time the business has at its current burn rate before it will need to take on debt or dilute shareholders to raise more money.

Valuation Model

Key Score

1.00

Very Bad

Management

5.00

Very Good

Growth

3.00

Average

Profitability

2.00

Bad

Fin. Health

2.00

Bad

Dividends

--

--

Analyst

4.00

Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

2 new filings were in the last 7 days

Filter Form Types

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-07 07:37:03

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-07 07:32:40

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-09 07:39:06

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-06 08:03:17

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 20:08:43

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-31 08:24:54

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-26 20:12:26

Form SCHEDULE 13D/A

Unknown Form Type

Filed on 2026-02-25 21:51:53

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-24 20:05:58

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-24 20:05:12

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-24 20:05:07

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-24 20:05:00

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$24.15

197.4%

Avg:

$15.10

85.9%

Low:

$11.11

36.8%

(% change is relative to the current stock price: $8.12)

Analyst Recommendations

Go to Analyst Tab

4.27

Very Good

36%

Strong Buy (4)

55%

Buy (6)

9%

Hold (1)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://immunitybio.com/
Address
3530 John Hopkins Court, San Diego CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1326110

ImmunityBio, Inc. is a clinical stage immunotherapy company. The company is headquartered in San Diego, California and currently employs 691 full-time employees. The company went IPO on 2015-07-28. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.

IPO Date

2015-07-28

Industry

Biotechnology

Total Employees

691

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences